HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Permissions Request Permissions Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via ISI Web of Science (1) Citing Articles via Google Scholar Google Scholar Articles by Khuê, P. M. Search for Related Content PubMed PubMed Citation Articles by Khuê, P. M.

A 10-year prospective surveillance of Mycobacterium tuberculosis drug resistance in France 1995–2004

¹ Laboratory of Bacteriology and Hygiene, Pierre et Marie Curie-Paris6 University and, ² National Reference Centre for Mycobacteria and Antituberculosis Drug Resistance, APHP Pitié-Salpêtrière Hospital, Paris, and ³ Laboratory of Bacteriology, Haut Lévêque Hospital, Bordeaux, France.

CORRESPONDENCE: J. Robert, Laboratoire de Bactériologie-Hygiène, UFR de Médecine Pierre et Marie Curie Paris 6, 91 Boulevard de l'hôpital, 75634 Paris Cedex 13, France. Fax: 33 145827577. E-mail: jrobert{at}chups.jussieu.fr

Keywords: Isoniazid, resistance, rifampicin, surveillance, trend, tuberculosis

Received: March 28, 2007
Accepted June 7, 2007

Drug resistance surveillance and trend monitoring resistance rates bring some insights into tuberculosis (TB) control. The current study reports the characteristics of TB and drug resistance during a 10-yr prospective surveillance of culture-positive TB in France.

Data for the current study was collected from 1995–2004 via a sentinel network of laboratories from university hospitals that complied with the international recommendations for the surveillance of drug resistance. Susceptibility test results were performed in each individual laboratory.

Data on 13,283 patients were collected during the 10-yr period, 49% of whom had been born in France, 10% were HIV co-infected and 8% had previously been treated. As expected, previously treated and HIV co-infected patients were more likely to harbour resistant strains, especially rifampicin (RMP)-resistant strains. Among new patients, the mean resistance rate to at least one drug was 8.8%, and there was an upward trend in resistance to isoniazid and RMP (0.8–1%) related to the increase in the proportion of patients who had been born outside of France (38–53%). Among previously treated patients, the mean resistance rate to one drug was 20.6% and there was no significant time trend in resistance rates.

The sentinel network provided valuable data on trends regarding the characteristics of tuberculosis and on drug resistance rates and reinforced the interest of analysing data by country of birth and history of treatment.